DƯỢC LÍ Goodman & Gilman's The Pharmacological Basis of Therapeutics 12th, 2010

Perelson AS, Neumann AU, Markowitz M, et al. HIV-1 dynamics
in vivo: Virion clearance rate, infected cell life-span, and
viral generation time. Science, 1996, 271:1582–1586.
Perry CM, Faulds D. Lamivudine: A review of its antiviral activity,
pharmacokinetic properties and therapeutic efficacy in the
management of HIV infection. Drugs, 1997, 53:657–680.
Perry CM, Noble S. Saquinavir soft-gel capsule formulation: A
review of its use in patients with HIV infection. Drugs, 1998,
55:461–486.
Piscitelli SC, Gallicano KD. Interactions among drugs for HIV
and opportunistic infections. N Engl J Med, 2001, 344:984–996.
Plosker GL, Noble S. Indinavir: A review of its use in the management
of HIV infection. Drugs, 1999, 58:1165–1203.
Rainey PM, Friedland G, McCance-Katz EF, et al. Interaction
of methadone with didanosine and stavudine. J Acquir Immune
Defic Syndr, 2000, 24:241–248.
Riddler SA, Haubrich R, DiRienzo, et al. Class-sparing regimens
for initial treatment of HIV-1 infection. N Engl J Med, 2008,
358:2095–2106.
Robbins BL, Wilcox CK, Fridland A, Rodman JH. Metabolism
of tenofovir and didanosine in quiescent or stimulated human
peripheral blood mononuclear cells. Pharmacotherapy, 2003,
23:695–701.
Roberts NA, Martin JA, Kinchington D, et al. Rational design
of peptide-based HIV proteinase inhibitors. Science, 1990,
248:358–361.
Rotger M, Taffe P, Bleiber G, et al. Gilbert syndrome and the
development of antiretroviral therapy-associated hyperbilirubinemia.
J Infect Dis, 2005, 192:1381–1386.
Rufo P, Lin PW, Andrade A, et al. Diarrhea-associated HIV-1
aspartyl protease-inhibitors potentiate muscarinic activation
of Cl – secretion by T84 cells via prolongation of cytosolic
Ca 2+ signaling. Am J Physiol Cell Physiol, 2004, 286:
998–1008.
Saag MS. Emtricitabine, a new antiretroviral agent with activity
against HIV and hepatitis B virus. Clin Infect Dis, 2006,
42:126–131.
Saag MS, Sonnerborg A, Torres RA, et al. Antiretroviral effect
and safety of abacavir alone and in combination with zidovudine
in HIV-infected adults. Abacavir Phase 2 Clinical Team.
AIDS, 1998, 12:F203–F209.
Scott LJ, Perry CM. Delavirdine: A review of its use in HIV
infection. Drugs, 2000, 60:1411–1444.
Shafer RW, Smeaton LM, Robbins GK, et al., for the AIDS
Clinical Trials Group 384 Team. Comparison of four-drug regimens
and pairs of sequential three-drug regimens as initial therapy
for HIV-1 infection. N Engl J Med, 2003, 349: 2304–2315.
Sheran M. The nonnucleoside reverse transcriptase inhibitors
efavirenz and nevirapine in the treatment of HIV. HIV Clin
Trials, 2005, 6:158–168.
Siliciano JD, Kajdas J, Finzi D, et al. Long-term follow-up studies
confirm the stability of the latent reservoir for HIV-1 in
resting CD4+ T cells. Nature Med, 2003, 9:727–728.
Steigbigel RT, Cooper DA, Kumar PN, et al. Raltegravir with
optimized background therapy for resistant HIV-1 infection.
N Engl J Med, 2008, 359:339–354.
Stone ND, Dunaway SB, Flexner C, et al. Multiple dose escalation
study of the safety, pharmacokinetics, and biologic activity
of oral AMD070, a selective CXCR4 receptor inhibitor, in
human subjects (ACTG A5191). Antimicrob Agents Chemother,
2007, 51:2351–2358.
Taylor S, Back DJ, Workman J, et al. Poor penetration of the
male genital tract by HIV-1 protease inhibitors. AIDS, 1999,
13:859–860.
Tripuraneni NS, Smith PR, Weedon J, et al. Prognostic factors in
lactic acidosis syndrome caused by nucleoside reverse transcriptase
inhibitors: Report of eight cases and review of the
literature. AIDS Patient Care STDs, 2004, 18:379–384.
Wainberg MA, Drosopoulos WC, Salomon H, et al. Enhanced
fidelity of 3TC-selected mutant HIV-1 reverse transcriptase.
Science, 1996, 271:1282–1285.
Wainberg MA, Miller MD, Quan Y, et al. In vitro selection and
characterization of HIV-1 with reduced susceptibility to
PMPA. Antivir Ther, 1999, 4:87–94.
Washington CB, Flexner C, Sheiner LB, et al. Effect of simultaneous
versus staggered dosing on pharmacokinetic interactions
of protease inhibitors. Clin Pharmacol Ther, 2003, 73:
406–416.
Wei X, Ghosh SK, Taylor ME, et al. Viral dynamics in human
immunodeficiency virus type 1 infection. Nature, 1995, 373:
117–122.
Werth B. The Billion Dollar Molecule: One Company’s Quest
for the Perfect Drug. Simon & Schuster, New York, 1994.
When to Start Consortium. Timing of initiation of antiretroviral therapy
in AIDS-free HIV-1-infected patients: A collaborative analysis
of 18 HIV cohort studies. Lancet, 2009, 373:1352–1363.
Wild CT, Shugars DC, Greenwell TK, et al. Peptides corresponding
to a predictive alpha-helical domain of human immunodeficiency
virus type 1 gp41 are potent inhibitors of virus
infection. Proc Natl Acad Sci USA, 1994, 91:9770–9774.
Wilkin TJ, McKinnon JE, DiRienzo AG, et al. Regimen simplification
to atazanavir-ritonavir alone as maintenance antiretroviral
therapy: Final 48-week clinical and virologic outcomes.
J Infect Dis, 2009, 199:866–871.
1663
CHAPTER 59
ANTIRETROVIRAL AGENTS AND TREATMENT OF HIV INFECTION